Market Research Logo

Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016

Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016

Summary



Global Markets Direct’s, ‘Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Otsuka Holdings Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Otsuka Holdings Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Otsuka Holdings Co., Ltd.
  • The report provides overview of Otsuka Holdings Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Otsuka Holdings Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Otsuka Holdings Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Otsuka Holdings Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Otsuka Holdings Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Otsuka Holdings Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Otsuka Holdings Co., Ltd. Snapshot
Otsuka Holdings Co., Ltd. Overview
Key Information
Key Facts
Otsuka Holdings Co., Ltd. - Research and Development Overview
Key Therapeutic Areas
Otsuka Holdings Co., Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Otsuka Holdings Co., Ltd. - Pipeline Products Glance
Otsuka Holdings Co., Ltd. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Otsuka Holdings Co., Ltd. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Otsuka Holdings Co., Ltd. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Otsuka Holdings Co., Ltd. - Drug Profiles
(carteolol hydrochloride + latanoprost)
Product Description
Mechanism of Action
R&D Progress
(tipiracil hydrochloride + trifluridine)
Product Description
Mechanism of Action
R&D Progress
levetiracetam
Product Description
Mechanism of Action
R&D Progress
ponatinib hydrochloride
Product Description
Mechanism of Action
R&D Progress
tolvaptan
Product Description
Mechanism of Action
R&D Progress
(aripiprazole + sertraline)
Product Description
Mechanism of Action
R&D Progress
(gimeracil + oteracil + tegafur)
Product Description
Mechanism of Action
R&D Progress
aripiprazole ER
Product Description
Mechanism of Action
R&D Progress
AVP-786
Product Description
Mechanism of Action
R&D Progress
brexpiprazole
Product Description
Mechanism of Action
R&D Progress
delamanid
Product Description
Mechanism of Action
R&D Progress
nabiximols
Product Description
Mechanism of Action
R&D Progress
rebamipide
Product Description
Mechanism of Action
R&D Progress
(dextromethorphan + quinidine sulfate)
Product Description
Mechanism of Action
R&D Progress
OCV-501
Product Description
Mechanism of Action
R&D Progress
OPA-15406
Product Description
Mechanism of Action
R&D Progress
OPS-2071
Product Description
Mechanism of Action
R&D Progress
probucol
Product Description
Mechanism of Action
R&D Progress
tetomilast
Product Description
Mechanism of Action
R&D Progress
OPA-6566
Product Description
Mechanism of Action
R&D Progress
OPB-111001
Product Description
Mechanism of Action
R&D Progress
LPC-01
Product Description
Mechanism of Action
R&D Progress
LUAF-20513
Product Description
Mechanism of Action
R&D Progress
OCVC-02
Product Description
Mechanism of Action
R&D Progress
OPB-111077
Product Description
Mechanism of Action
R&D Progress
OPC-108459
Product Description
Mechanism of Action
R&D Progress
OPC-39436
Product Description
Mechanism of Action
R&D Progress
OPC-64005
Product Description
Mechanism of Action
R&D Progress
OPC-28326
Product Description
Mechanism of Action
R&D Progress
Otsuka Holdings Co., Ltd. - Pipeline Analysis
Otsuka Holdings Co., Ltd. - Pipeline Products by Target
Otsuka Holdings Co., Ltd. - Pipeline Products by Route of Administration
Otsuka Holdings Co., Ltd. - Pipeline Products by Molecule Type
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates
Otsuka Holdings Co., Ltd. - Dormant Projects
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
(gimeracil + oteracil + tegafur)
(tipiracil hydrochloride + trifluridine)
AVP-13358
AZD-2479
brexpiprazole
dasatinib
OCV-101
OPB-31121
OPB-51602
rebamipide
Otsuka Holdings Co., Ltd. - Company Statement
Otsuka Holdings Co., Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Otsuka Holdings Co., Ltd., Key Information
Otsuka Holdings Co., Ltd., Key Facts
Otsuka Holdings Co., Ltd. - Pipeline by Indication, 2016
Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2016
Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2016
Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2016
Otsuka Holdings Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
Otsuka Holdings Co., Ltd. - Pre-Registration, 2016
Otsuka Holdings Co., Ltd. - Phase III, 2016
Otsuka Holdings Co., Ltd. - Phase II, 2016
Otsuka Holdings Co., Ltd. - Phase I, 2016
Otsuka Holdings Co., Ltd. - Preclinical, 2016
Otsuka Holdings Co., Ltd. - Pipeline by Target, 2016
Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2016
Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2016
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates, 2016
Otsuka Holdings Co., Ltd. - Dormant Developmental Projects,2016
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products, 2016
Otsuka Holdings Co., Ltd., Other Locations
Otsuka Holdings Co., Ltd., Subsidiaries
List of Figures
Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Indication, 2016
Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2016
Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2016
Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2016
Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Target, 2016
Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2016
Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2016
Otsuka Holdings Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report